



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>6</sup> : <b>A61K 31/40, C07D 207/12</b></p>	<p><b>A1</b></p>	<p>(11) International Publication Number: <b>WO 97/09040</b></p> <p>(43) International Publication Date: 13 March 1997 (13.03.97)</p>
<p>(21) International Application Number: PCT/DK96/00373</p> <p>(22) International Filing Date: 6 September 1996 (06.09.96)</p> <p>(30) Priority Data: 0992/95 8 September 1995 (08.09.95) DK</p> <p>(71) Applicant (for all designated States except US): NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsværd (DK).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): LUNDGREN, Karsten [DK/DK]; N. Jespersensvej 25, DK-2000 Frederiksberg (DK). JAKOBSEN, Palle [DK/DK]; Langkær Vænge 14, DK-3500 Værløse (DK). KRISTIANSEN, Marit [DK/DK]; Gustav Esmann's Allé 2, DK-2860 Søborg (DK). NØRSKOV-LAURITSEN, Leif [DK/DK]; Strandvejen 80, DK-4733 Tappernoeje (DK). NÆRUM, Lars [DK/DK]; Alrunevej 14, DK-2900 Hellerup (DK).</p> <p>(74) Common Representative: NOVO NORDISK A/S; Corporate Patents, Novo Allé, DK-2880 Bagsværd (DK).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> With international search report.</p>
<p>(54) Title: 2-ALKYLPYRROLIDINES</p> <p>(57) Abstract</p> <p>(2R, 3R, 4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine and other substituted 2-methylpyrrolidines can be used for the treatment of diabetes.</p>		

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## 2-ALKYLPYRROLIDINES

### Field of this invention

The present invention relates to the use of 2-alkyl-pyrrolidines in the treatment of diabetes and pharmaceutical  
5 compositions containing these compounds.

### Background of this invention

Diabetes is characterized by an impaired glucose metabolism manifesting itself among other things by an elevated blood glucose level in the diabetic patients. Underlying defects  
10 lead to a classification of diabetes into two major groups: type 1 diabetes, or insulin demanding diabetes mellitus (IDDM), which arises when patients lack  $\beta$ -cells producing insulin in their pancreatic glands, and type 2 diabetes, or non-insulin dependent diabetes mellitus (NIDDM), which  
15 occurs in patients with an impaired  $\beta$ -cell function in association with a range of other abnormalities.

Type 1 diabetic patients are currently treated with insulin. The majority of type 2 diabetic patients are treated either with sulfonylureas that stimulate  $\beta$ -cell  
20 function, with  $\alpha$ -glucosidase inhibitors which decrease carbohydrate uptake from the intestine in association with meals, or with agents that enhance the tissue sensitivity of the patients towards insulin or with insulin. Among the agents applied to enhance tissue sensitivity towards insulin, metformin is a representative example. Examples of  $\alpha$ -  
25 glucosidase inhibitors are acarbose and voglibose.

Even though sulfonylureas and  $\alpha$ -glucosidase inhibitors are widely used in the treatment of NIDDM, this therapy is, in most instances, not satisfactory: Thus, in a  
30 large number of NIDDM patients, sulfonylureas and  $\alpha$ -glucosidase inhibitors do not suffice to normalize blood sugar levels and the patients are, therefore, at high risk for acquiring diabetic complications. Also, many patients gradually lose the ability to respond to treatment with  
35 sulfonylureas and are gradually forced into insulin treatment. This shift of patients from oral hypoglycaemic agents to insulin therapy is usually ascribed to exhaustion of the  $\beta$ -cells in NIDDM patients.

In normals as well as in diabetics, the liver produces glucose in order to avoid hypoglycemia. This glucose production is derived either from the release of glucose from glycogen stores or from gluconeogenesis, which is a de novo intracellular synthesis of glucose. In type 2 diabetes, however, the regulation of hepatic glucose output is poorly controlled and is increased, and may be doubled after an overnight fast. Moreover, in these patients there exists a strong correlation between the increased fasting plasma glucose levels and the rate of hepatic glucose production (reviewed in R.A. De Fronzo: Diabetes 37 (1988), 667 - 687; A. Consoli: Diabetes Care 15 (1992), 430 - 441; and J.E. Gerich: Horm.Metab.Res. 26 (1992), 18 - 21). Similarly, if type 1 diabetes is not properly controlled by insulin treatment, hepatic glucose production, particularly from glycogen, will be increased and result in fasting hyperglycemia.

Since existing forms of therapy of diabetes does not lead to sufficient glycaemic control and therefore are unsatisfying, there is a great demand for novel therapeutic approaches. Since the liver in diabetes is known to have an increased glucose production, compounds inhibiting this activity are highly desirable.

Recently, patents on inhibitors of the liver specific enzyme, glucose-6-phosphatase, which is necessary for the release of glucose from the liver, have been filed, for example German Offenlegungsschrift Nos. 4,202,183 and 4,202,184 and Japanese patent application No. 4-58565. All these known compounds are benzene derivatives.

International patent application having publication No. WO 92/16640 relates to di-, tri- and tetrasaccharides that are substrates or inhibitors of glycosyltransferase and glycosidase enzymes. Some specific compounds mentioned therein

are 2,3,4,5-tetrahydroxypiperidine, 3,4,5-trihydroxy-6-methylpiperidine and 3,4-dihydroxy-5-methylpiperidine.

International Patent Application No. WO 92/21657 relates to certain  $\omega$ -deoxyazapyranoses, e.g. 3,4-dihydroxy-5-methylpiperidine mentioned in Claim 16 thereof. It is stated that these compounds have glucosidase inhibiting properties.

European patent application having publication No. 528,495 A1 relates to a class of azacyclic compounds, i.e. compounds comprising an azacyclic ring system substituted by arylmethoxy or an arylmethylthio moiety. These compounds may be useful as tachykinin antagonists.

European patent application having publication No. 375,651 A1 relates to 1,4-dideoxy-1,4-imino-L-allitol and derivatives thereof having glycosidase inhibitory activity.

Moreover, scientifically it is well realized that inhibition of glycogen phosphorylase is a suitable target for the treatment of diabetes (Martin et al., 1991; Biochemistry 30: 10101-16; Oikonomakos et al., 1994; Eur. J. Drug Metab. Pharmacokin. 3: 185-92). These groups have used glucose analogs.

European patent application No. 422,307 relates to preparation of N-glycosyl 1,4-dideoxy-1,4-imino-D-arabinitols as  $\alpha$ -glycosidase inhibitors. These compounds are said to be useful in the treatment of diabetes mellitus.

European patent application No. 389,723 relates to the preparation of iminoarabinitol derivatives as  $\alpha$ -glucosidase inhibitors.

US patent No. 4,973,602 relates to antiviral (2S,3S,4S) pyrrolidines having benzyloxycarbonyl or an optionally substituted alkylphenyl group in the 1-position. In said US patent, (2S,3S,4S)-1-([4-chlorophenyl]methyl-2-hydroxy-methyl-3,4-dihydroxypyrrolidine is specifically mentioned.

European patent application No. 367,747 relates to antiviral (2S,3S,4S) pyrrolidines, e.g. (2S,3S,4S)-2-hydroxymethyl-3,4-dihydroxypyrrolidines having methyl, butyl, hexyl, nonyl, propionyl, 2-hydroxyethyl or 5-hydroxy-  
5 pentyl in the 1-position.

European patent application No. 322.395 describes some pyrrolidines and piperidines, which can be used for the treatment of AIDS. Examples of specific compounds mentioned therein are 2-hydroxymethyl-3,4-dihydroxypyrrolidine and the  
10 corresponding 1-methyl derivative.

One object of the present invention is to furnish compounds which can be used as medicaments.

A further object of this invention is to furnish compounds which can effectively be used in the treatment of  
15 diabetes.

A still further object of this invention is to furnish compounds which can effectively be used as inhibitors of glucose production from the liver.

A further object of this invention is to furnish  
20 compounds which can effectively be used as phosphorylase inhibitors.

#### Brief description of this invention

The present invention relates to compounds of the general formula I stated in the claims below.

25 Surprisingly, it has been found that the compounds stated in the claims, below, have interesting pharmacological properties. For example, the compounds can be used in the treatment of diabetes. Especially, the compounds are active as inhibitors of glucose production from the liver.  
30 Consequently, the compounds can be used for the treatment of the increased plasma glucose levels in diabetics.

Detailed description of this invention

Hereinafter, the term alkyl, when used alone or in combination with another moiety, is a straight or branched saturated hydrocarbon chain group which preferably contains not more than 8 carbon atoms, more preferred not more than 4 carbon atoms. Especially preferred alkyl groups are methyl, ethyl, propyl and isopropyl.

The term halogen as used herein refers to chloro, bromo or fluoro, preferably fluoro. Preferably, N-alkylamino is N-methylamino. Preferably, N,N-dialkylamino is N,N-dimethylamino. The term acyl as used herein refers to carbonyl substituted with hydrogen, alkyl or phenyl. Herein, cycloalkyl preferably contains 3-7 carbon atoms, more preferred 3-6 carbon atoms. Alkoxy preferably is methoxy or ethoxy. Alkoxycarbonyl preferably is methoxycarbonyl or ethoxycarbonyl. Aralkyl preferably is benzyl. Trifluoroalkyl preferably is trifluoromethyl or 2,2,2-trifluoroethyl. Alkene preferably contains not more than 8 carbon atoms and preferably is allyl. The term "one or more" substituents preferably is 1-3 substituents, most preferred 1.

A subgroup of compounds to be used according to this invention are compounds of formula I wherein the two substituents designated by the symbols  $R^3$  and  $R^5$  are situated at the same side of the plane formed by the 5 membered nitrogen containing ring, and  $R^4$  is situated at the opposite side of the plane formed by the 5 membered nitrogen containing ring. Such compounds are either (2S,3S,4S)-2-alkylpyrrolidines or (2R,3R,4R)-2-alkylpyrrolidines. Among these compounds, the (2R,3R,4R)-2-alkylpyrrolidines are preferred.

Examples of compounds to be used according to this invention are compounds of formula I wherein  $R^1$  is alkyl which optionally is substituted with one or more of the following

groups: hydroxy, alkoxy, amino, N-alkylamino, N,N-dialkylamino, alkoxycarbonyl, cycloalkyl or optionally substituted phenyl.

Another example of compounds to be used according to  
5 this invention are compounds of formula I wherein  $R^1$  is phenylalkyl wherein the phenyl moiety optionally is substituted with one or more of the following groups: halogen, hydroxy, alkoxy, trifluoromethyl or cyano.

Another subgroup of compounds to be used according to this  
10 invention are compounds of formula I wherein  $R^3$  and  $R^4$  each are hydroxy, and  $R^5$  is hydroxymethyl.

The compounds of formula I may be presented as a mixture of isomers which, if desired, may be resolved into the individual pure enantiomers. This resolution may con-  
15 veniently be performed by fractional crystallization from various solvents, of the salts of compounds of the formula I with optical active acids or by other methods known per se, for example, chiral column chromatography. This invention includes all isomers, whether resolved or mixtures thereof.

20 Examples of pharmaceutically acceptable salts are acid addition salts with non-toxic acids, either inorganic acids such as hydrochloric acid, sulphuric acid and phosphoric acid, or organic acids such as formic acid, acetic acid, propionic acid, succinic acid, gluconic acid, lactic acid,  
25 citric acid, ascorbic acid, benzoic acid, embonic acid, methanesulphonic acid and malonic acid.

Preferred compounds to be used according to this invention are 3,4-dihydroxy-2-hydroxymethylpyrrolidine, 3,4-dihydroxy-2-hydroxymethyl-1-methylpyrrolidine, 1-cyclopropylmethyl-  
30 3,4-dihydroxy-2-hydroxymethylpyrrolidine, 3,4-dihydroxy-2-hydroxymethyl-1-propylpyrrolidine, 1-butyl-3,4-dihydroxy-2-hydroxymethylpyrrolidine, 3,4-dihydroxy-2-hydroxymethyl-1-




(2,2,2-trifluoroethyl)pyrrolidine, 1-benzyl-3,4-dihydroxy-2-hydroxymethylpyrrolidine, 3,4-dihydroxy-2-hydroxymethyl-1-(2-hydroxyethyl)pyrrolidine, 3,4-dihydroxy-2-hydroxymethyl-1-(1,3-dihydroxyprop-2-yl)pyrrolidine, 3,4-dihydroxy-2-  
5 hydroxymethyl-1-(2,3-dihydroxyprop-1-yl)pyrrolidine, 1-(2-aminoethyl)-3,4-dihydroxy-2-hydroxymethylpyrrolidine and salts and hydrates thereof, preferably (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine, (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethyl-1-methylpyrrolidine, (2R,3R,4R)-1-  
10 cyclopropylmethyl-3,4-dihydroxy-2-hydroxymethylpyrrolidine, (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethyl-1-propylpyrrolidine, (2R,3R,4R)-1-butyl-3,4-dihydroxy-2-hydroxymethylpyrrolidine, (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethyl-1-(2,2,2-trifluoroethyl)pyrrolidine, (2R,3R,4R)-1-benzyl-  
15 3,4-dihydroxy-2-hydroxymethylpyrrolidine, (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethyl-1-(2-hydroxyethyl)pyrrolidine, (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethyl-1-(2,3-dihydroxyprop-1-yl)pyrrolidine, (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethyl-1-(1,3-dihydroxyprop-2-yl)pyrrolidine, (2R,3R,4R)-1-  
20 (2-aminoethyl)-3,4-dihydroxy-2-hydroxymethylpyrrolidine, (2S,3S,4S)-3,4-dihydroxy-2-hydroxymethylpyrrolidine, (2S,3S,4S)-3,4-dihydroxy-2-hydroxymethyl-1-methylpyrrolidine, (2S,3S,4S)-1-cyclopropylmethyl-3,4-dihydroxy-2-hydroxymethylpyrrolidine, (2S,3S,4S)-3,4-dihydroxy-2-  
25 hydroxymethyl-1-propylpyrrolidine, (2S,3S,4S)-1-butyl-3,4-dihydroxy-2-hydroxymethylpyrrolidine, (2S,3S,4S)-3,4-dihydroxy-2-hydroxymethyl-1-(2,2,2-trifluoroethyl)pyrrolidine, (2S,3S,4S)-1-benzyl-3,4-dihydroxy-2-hydroxymethylpyrrolidine, (2S,3S,4S)-3,4-dihydroxy-2-hydroxymethyl-1-(2-  
30 hydroxyethyl)pyrrolidine, (2S,3S,4S)-3,4-dihydroxy-2-hydroxymethyl-1-(2,3-dihydroxyprop-1-yl)pyrrolidine, (2S,3S,4S)-3,4-dihydroxy-2-hydroxymethyl-1-(1,3-dihydroxyprop-2-yl)pyrrolidine, (2S,3S,4S)-1-(2-aminoethyl)-3,4-dihydroxy-2-hydroxymethylpyrrolidine and salts and hydrates  
35 thereof.

Generally, the compounds of formula I are prepared by methods known per se by the skilled art worker, for example as described in the following. The compounds of formula I can be prepared by joining the C-1 and C-4 of xylose  
5 together with nitrogen to form the pyrrolidine ring as described in Tetrahedron 42 (1986), 5685 et seq. A variety of functional groups can be introduced in the compounds prepared as outlined above by methods well known to those skilled in the art.

10 More specifically, the compounds of formula I can be prepared as follows:


a) Reacting a compound of the general formula II



(II)

wherein  $R^2$ ,  $R^3$ ,  $R^4$ , and  $R^5$  are as defined in the claims  
15 below, with an aldehyde in presence of a reducing agent among which sodium cyanoborohydride is preferred, to form a compound of formula I.

b) Reacting a compound of the general formula II




(II)

wherein  $R^2$ ,  $R^3$ ,  $R^4$ , and  $R^5$  are as defined in the claims below, with a compound of the general formula  $R^1Y$ , wherein  $R^1$  is as defined in the claims below, and  $Y$  is a leaving group, to form a compound of formula I. The reaction is

5 carried out under alkaline conditions, i.e. in the presence of a base.

The leaving group,  $Y$ , may be any suitable leaving group as for example halogen.


c) Reacting a compound of the general formula III



wherein  $R^1$  either is as defined in the claims below or is a readily removable protection group, i.e. benzyl,  $R^2$  is as defined in the claims below and  $R^3$  and  $R^4$  are protected hydroxy, i.e. benzyloxy, with a halogenating agent such as

15 thionyl chloride, thionyl bromide, or diethylaminosulfur trifluoride (DAST) and subsequent removal of the protection groups to form a compound of formula I, wherein  $R^1$ ,  $R^3$ , and  $R^4$  are as defined in the claims below, and  $R^5$  is methyl substituted with halogen.


20 d) Reacting a compound of the general formula IV



wherein R<sup>1</sup> either is as defined in the claims below or is a readily removable protection group, i.e. benzyl, R<sup>2</sup> is as defined in the claims below, R<sup>3</sup> and R<sup>4</sup> are protected hydroxy, i.e. benzyloxy, and X is a leaving group, with a  
 5 compound of the general formula NHR<sup>6</sup>R<sup>7</sup>, wherein the two substituents R<sup>6</sup> and R<sup>7</sup> may both be alkyl, or one is alkyl and the other is hydrogen or together with NH R<sup>6</sup> and R<sup>7</sup> form phthalimide, and subsequent removal of the protection groups to form the compounds of formula I, wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, and  
 10 R<sup>4</sup> are as defined in the claims below, and R<sup>5</sup> is methyl substituted with amino, N-alkylamino, or N,N-dialkylamino.

The leaving group, X, may be any suitable leaving group as for example halogen.

e) Reacting a compound of the general formula I



15

(I)

wherein R<sup>1</sup> and R<sup>2</sup> are as defined in the claims below, and one or two of the groups R<sup>3</sup> and R<sup>4</sup> is hydroxy and the remaining is protected hydroxy, i.e. benzyl, R<sup>5</sup> is as defined in the claims below or is a corresponding protected  
 20 group, with a halogenating agent such as thionyl chloride, thionyl bromide or diethylaminosulfur trifluoride (DAST) and subsequent removal of the protection groups to form a compound of the formula I, wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>5</sup> are as

defined in the claims below, and R<sup>3</sup> and R<sup>4</sup> are hydroxy or halogen, but not more than one of R<sup>3</sup> and R<sup>4</sup> is hydroxy.

#### Pharmaceutical Compositions

This invention further provides pharmaceutical compositions  
5 which comprise at least one compound of formula I or a pharmaceutically acceptable salt thereof in connection with a pharmaceutically acceptable carrier. Such compositions may be in the form of powders, solutions, or suspensions, which may or may not be divided in unit dosage form or in the form  
10 of capsules or tablets.

The pharmaceutical compositions of this invention may comprise carriers, diluents, absorption enhancers, tablet disintegrating agents and other ingredients which are conventionally used in the art. The powders and tablets preferably  
15 contain from 5 to 99%, more preferred from 10 to 90 % of the active ingredient. Examples of solid carriers are magnesium carbonate, magnesium stearate, dextrin, lactose, sugar, talc, gelatin, pectin, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, low melting waxes and cocoa butter.

20 Liquid compositions include sterile solutions, suspensions and emulsions suitable for parenteral injection.

The route of administration of the compositions containing a compound of formula I may be any route which effectively transports the active compound to its site of  
25 action, the oral or nasal route being preferred.

The regimen for any patient to be treated with the compositions according to the present invention should be determined by those skilled in the art. The daily dose to be administered in therapy can be determined by a physician and  
30 will depend on the particular compound employed, on the route of administration and on the age and the condition of the patient. A convenient daily dosage can be less than about 1 g, preferably in the range around 10 - 200 mg.

The present invention is further illustrated by the following examples which, however, are not to be construed as limiting the scope of protection.

The features disclosed in the foregoing description and  
5 in the following examples and claims may, both separately and in any combination thereof, be material for realising the invention in diverse forms thereof.

#### Example 1

(2R,3R,4R)-3,4-Dibenzyloxy-2-(benzyloxymethyl)pyrrolidine  
10 (Compound 1)

The title compound was prepared by the method described by Overkleeft et al., Tetrahedron 50 (1994), 4215-4224.

#### Example 2

(2R,3R,4R)-3,4-Dihydroxy-2-(hydroxymethyl)pyrrolidine,  
15 hydrochloride (Compound 2)

The title compound was prepared by the method described by Overkleeft et al., Tetrahedron 50 (1994), 4215-4224.

#### Example 3

(2R,3R,4R)-3,4-Dibenzyloxy-2-benzyloxymethyl-1-methyl-  
20 pyrrolidine (Compound 3)

A mixture of (2R,3R,4R)-3,4-dibenzyloxy-2-benzyloxymethyl-pyrrolidine (Compound 1) (0.5 g, 1.24 mmol), formic acid (10 ml) and 37 % formaldehyde (7.5 ml) was heated for 3 hours at reflux temperature and evaporated in vacuo. The residue was  
25 dissolved in a mixture of ethyl acetate (25 ml) and 1 N sodium hydroxide (25 ml). The organic phase was isolated,

washed once with water, dried over magnesium sulphate and evaporated in vacuo to give (2R,3R,4R)-3,4-dibenzyloxy-2-benzyloxymethyl-1-methylpyrrolidine (0.49 g, yield: 95%) as a golden oil.

5       <sup>1</sup>H-NMR (CDCl<sub>3</sub>) in ppm: δ 7.2-7.4 (15H, phenyl), 4.3-4.6 (6H, m, CH<sub>2</sub> in benzyl), 3.9 (2H, m, CH<sub>2</sub>O), 3.5-3.7 (2H, m, 2 CH-O-Bn), 3.15 (1H, d, CHCH<sub>2</sub>O), 2.4-2.6 (2H, m, CH<sub>2</sub>N), 2.4 (3H, s, CH<sub>3</sub>).

10       <sup>13</sup>C-NMR (CDCl<sub>3</sub>) in ppm: δ 138.4, 138.2, 128.4, 127.9, 127.8, 127.6, 127.5, 86.4, 81.6, 73.3, 71.5, 71.0, 70.9, 70.6, 60.4, 41.7.

#### Example 4

(2R,3R,4R)-3,4-Dihydroxy-2-hydroxymethyl-1-methylpyrrolidine, hydrochloride (Compound 4)

15 A mixture of (2R,3R,4R)-3,4-dibenzyloxy-2-benzyloxymethyl-1-methylpyrrolidine (Compound 3) (38 mg, 0.067 mmol), 10% Pd/C (30 mg), 4 N HCl (0.1 ml) and 99.9% ethanol (5 ml) was reduced in a Parr apparatus at 40 psi for 20 hours. The mixture was filtered and evaporated in vacuo to give  
20 (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethyl-1-methylpyrrolidine, hydrochloride (15 mg, yield 88%) as a yellow oil.

<sup>13</sup>C-NMR (CD<sub>3</sub>OD) in ppm: δ 79.1, 78.1, 75.8, 63.4, 60.7, 44.2

25

#### Example 5

(2R,3R,4R)-3,4-Dibenzyloxy-2-benzyloxymethyl-1-trifluoroacetylpyrrolidine (Compound 5)

(2R,3R,4R)-3,4-Dibenzyloxy-2-benzyloxymethylpyrrolidine (Compound 1) (0.5 g, 1.5 mmol) was suspended in ethyl 1,1,1-

trifluoroacetate (20 ml). The reaction mixture was heated at reflux temperature for 16 hours. The mixture was cooled and evaporated in vacuo. The residual oil was purified on a silica gel column with diethylether/hexan (1:1) as eluent giving (2R,3R,4R)-3,4-dibenzyloxy-2-benzyloxymethyl-1-trifluoroacetylpyrrolidine (0.5 g, yield: 67%) as an oil.

<sup>13</sup>C-NMR (CDCl<sub>3</sub>) in ppm: δ 51.4, 63.4, 66.5, 71.4, 71.6, 73.2, 79.8, 81.3, 116 (q), 127.6, 127.7, 127.9, 128.0, 128.4, 128.6, 137.1, 137.4, 138.1, 156(q).

10

Example 6

(2R,3R,4R) 3,4-Dibenzyloxy-2-benzyloxymethyl-1-(2,2,2-trifluoroethyl)pyrrolidine (Compound 6)

(2R,3R,4R)-3,4-Dibenzyloxy-2-benzyloxymethyl-1-trifluoroacetylpyrrolidine (Compound 5) (0.3 g, 0.6 mmol) was dissolved in tetrahydrofuran (20 ml). The mixture was cooled to 0°C and 1 M borane-tetrahydrofuran complex (0.6 ml, 6 mmol) added under nitrogen. The reaction mixture was stirred at 0°C for 2 hours then refluxed for 2 hours. The mixture was cooled and poured into methanol (100 ml). Evaporation in vacuo gave (2R,3R,4R)-3,4-dibenzyloxy-2-benzyloxymethyl-1-(2,2,2-trifluoroethyl)pyrrolidine (0.3 g) as an oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) in ppm: δ 2.95 (q,1H); 3.15 (m,2H); 3.5 (d,1H); 3.7 (q,3H); 3.9 (m,1H); 4.2 (m,1H); 4.6 (m,6H); 7.45 (s,15H).

<sup>13</sup>C-NMR (CDCl<sub>3</sub>) in ppm: δ 54.9, 55.5, 56.2, 56.8, 58.6, 68.9, 71.2, 71.6, 72.0, 73.4, 81.8, 84.6, 127.7, 127.9, 128.2, 138.1, 138.3.

Example 7

(2R,3R,4R)-3,4-Dihydroxy-2-hydroxymethyl-1-(2,2,2-trifluoroethyl)pyrrolidine (compound 7)



(2R,3R,4R)-3,4-Dibenzyloxy-2-benzyloxymethyl-1-(2,2,2-trifluoroethyl)pyrrolidine (Compound 6) (0.3 g, 0.6 mmol) was dissolved in 96% ethanol (30 ml), and 10% Pd/C (0.1 g) was added under N<sub>2</sub>. The compound was reduced in a Parr apparatus  
5 (40 Psi) for 16 hours. The reaction mixture was filtered and evaporated in vacuo giving (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethyl-1-(2,2,2-trifluoroethyl)pyrrolidine (0.09 g) as an brown oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) in ppm: δ 3.3 (m, 1H); 3.4 (m, 2H); 3.7  
10 (t, d, 2H); 3.8 (t broad, 2H); 3.9-4.1 (m, 2H); 4.5 (broad s, OH).

#### Example 8

(2R,3R,4R)-3,4-Dibenzyloxy-2-benzyloxymethyl-1-cyclopropylmethylpyrrolidine, hydrochloride (Compound 8)

15 (2R,3R,4R)-3,4-Dibenzyloxy-2-benzyloxymethylpyrrolidine (Compound 1) (0.25 g, 0.62 mmol) was dissolved in methylisobutylketone (15 ml). Potassium carbonate (0.17 g, 1.2 mmol) and potassium iodide (0.03 g, 0.18 mol) was added. After stirring for 10 min at 25°C cyclopropylmethylbromide  
20 (0.078 ml, 0.81 mmol) was added. The mixture was stirred under a N<sub>2</sub> atmosphere at 80°C for 24 hours and evaporated in vacuo. Water (20 ml) was added and extraction with methylene chloride (3 x 20 ml), drying of the organic phases with magnesium sulphate and evaporation of the solvent in vacuo  
25 afforded a yellow oil. Purification of the crude product twice on a silica gel column (1: Eluent: CH<sub>2</sub>Cl<sub>2</sub>/MeOH (19:1) and 2: Eluent: CH<sub>2</sub>Cl<sub>2</sub>/MeOH (39:1)) gave (2R,3R,4R)-3,4-dibenzyloxy-2-benzyloxymethyl-1-cyclopropylmethylpyrrolidine (0.213 g, yield: 75%) as an oil.

30 <sup>1</sup>H-NMR (CDCl<sub>3</sub>) in ppm: δ 7.28 (m, 15H); 4.5 (m, 6H); 3.8 (broad s, 2H); 3.70-3.45 (m, 2H); 3.38 (s) and 3.32 (s) (alltogether 1H); 2.86 (dd, 1H); 2.74 (m, 1H); 2.63 (dd,

1H); 2.11 (dd, 1H); 1.0-0.8 (m, 1H); 0.46 (t, 2H); 0.10 (d, 2H).

Conversion of the free base into the hydrochloride salt using 2M HCl(g) in diethylether gave (2R,3R,4R)-2-benzyloxymethyl-3,4-dibenzyloxy-1-cyclopropylmethylpyrrolidine, hydrochloride (0.14 g, yield 46%), melting point: 66-67°C.

#### Example 9

(2R,3R,4R)-1-Cyclopropylmethyl-3,4-dihydroxy-2-hydroxymethylpyrrolidine, hydrochloride (Compound 9).

To a solution of (2R,3R,4R)-3,4-dibenzyloxy-2-benzyloxymethyl-1-cyclopropylmethylpyrrolidine, hydrochloride (Compound 8) (0.14 g, 0.28 mmol) in 96% ethanol (15 ml) was added 10% Pd/C (50 mg) and 1 M hydrochloric acid (0.1 ml). The reaction mixture was hydrogenated in Parr apparatus at 40 psi for 24 hours. The mixture was filtered and concentrated in vacuo giving (2R,3R,4R)-1-cyclopropylmethyl-3,4-dihydroxy-2-hydroxymethylpyrrolidine, hydrochloride as a yellow oil (0.063 g, yield: 100%).

<sup>1</sup>H-NMR (CD<sub>3</sub>OD) in ppm: δ 3.96 (broad s, 2H); 3.90 (s, 1H); 3.71-3.39 (m, 4H); 3.00 (dd, 1H); 1.24-1.08 (m, 1H); 0.75 (d, 2H); 0.43 (t, 2H).

#### Example 10

(2R,3R,4R)-3,4-Dibenzyloxy-2-benzyloxymethyl-1-butylpyrrolidine (Compound 10).

(2R,3R,4R)-3,4-Dibenzyloxy-2-benzyloxymethylpyrrolidine (Compound 1) (0.7 g, 1.7 mmol) was dissolved in dry methanol. Butyric aldehyde (0.153 ml, 1.7 mmol) and sodium cyanoborohydride (0.107 g, 1.7 mmol) was added. A solution

of anhydrous hydrogen chloride in diethylether (2 M) was added dropwise until pH 6. The resulting mixture was stirred for 24 hours at room temperature under a nitrogen atmosphere and evaporated in vacuo. Addition of 1M sodium hydroxide (50 ml), extraction of the product with diethylether (2 x 50 ml), drying of the organic phases with magnesium sulphate and evaporation of the solvent in vacuo gave the title compound as a crude oil (0.644 g). Purification of the crude product on a silica gel column (Eluent: methylene chloride/ 10 methanol (19:1)) afforded (2R,3R,4R)-3,4-dibenzyloxy-2-benzyloxymethyl-1-butylpyrrolidine (0.243 g, yield: 30%) as an oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) in ppm: δ 7.28 (m, 15H); 4.51 (m, 4H); 4.45 (2 s, 2H); 3.90 (m, 2H); 3.57 (m, 2H); 3.23 (s) and 15 3.18 (s) (alltogether 1H); 2.94-2.77 (m, 1H); 2.72 (dd, 1H); 2.55 (dd, 1H); 2.40-2.24 (m, 1H); 1.56-1.18 (m, 4H); 0.90 (t, 3H).

#### Example 11

(2R,3R,4R)-1-Butyl-3,4-dihydroxy-2-hydroxymethylpyrrolidine, 20 hydrochloride (Compound 11)

The title compound was synthesized as described for compound 9 using (2R,3R,4R)-3,4-dibenzyloxy-2-benzyloxymethyl-1-butylpyrrolidine (Compound 10) (0.243 g, 0.53 mmol), ethanol (30 ml), 10% Pd/C (0.07 g) and excess of 1M hydro-chloric 25 acid to convert the amine to the hydrochloride salt.

(2R,3R,4R)-1-Butyl-3,4-dihydroxy-2-hydroxymethylpyrrolidine, hydrochloride was obtained as a yellow syrup (0.098 g, yield: 82%).

<sup>1</sup>H-NMR (CD<sub>3</sub>OD) in ppm: δ 4.15 (s, 1H); 3.88 (m, 3H); 30 3.54 (m, 1H); 3.4 (m, 3H); 3.1 (m, 1H); 1.71 (m, 2H); 1.39 (m, 2H); 0.95 (t, 3H).

Example 12

(2R,3R,4R)-1-Acetyl-3,4-dibenzyloxy-2-benzyloxymethylpyrrolidine (Compound 12)

(2R,3R,4R)-3,4-Dibenzyloxy-2-benzyloxymethylpyrrolidine  
5 (Compound 1) (0.642 g, 1.6 mmol) was dissolved in dry methylene chloride (15 ml) under a nitrogen atmosphere. Triethylamine (0.288 ml, 2.1 mmol) and acetyl chloride (0.125 ml, 1.8 mmol) were added, and the mixture was stirred for 2 hours at room temperature. Water (20 ml) was added,  
10 the layers were separated and the water phase was extracted twice with methylene chloride (2 x 20 ml).

Drying of the combined organic phases with magnesium sulphate and evaporation of the solvent in vacuo gave the title compound as an crude oil (0.7 g, yield 99%).  
15 Purification on silica gel (Eluent: methylene chloride/methanol (19:1)) afforded (2R,3R,4R)-1-acetyl-3,4-dibenzyloxy-2-benzyloxymethylpyrrolidine (0.595 g, yield 83%) as an oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) in ppm: δ 7.28 (m, 15H); 4.65-4.33 (m, 7H); 4.12-3.46 (m, 6H); 2.06 (s) and 2.00 (s) (altogether 3H).  
20

Example 13

(2R,3R,4R)-1-Acetyl-3,4-dihydroxy-2-hydroxymethylpyrrolidine (Compound 13)

25 The title compound was synthesized as described for compound 9 using (2R,3R,4R)-1-acetyl-3,4-dibenzyloxy-2-benzyloxymethylpyrrolidine (Compound 12) (0.595 g, 1.3 mmol), ethanol (30 ml), methanol (10 ml), 10% Pd/C (0.10 g) and a catalytic amount of 1 M hydrochloric acid. Purification of the product  
30 on silica gel (Eluent: Ethyl acetate/methanol (1:1)) afford-

ed (2R,3R,4R)-1-acetyl-3,4-dihydroxy-2-hydroxymethyl-pyrrolidine (0.2 g, yield: 86%) as an oil.

<sup>1</sup>H-NMR (CD<sub>3</sub>OD) in ppm: δ 4.10 (broad s, 2H); 3.95-3.70 (m, 4H); 3.51-3.38 (m, 1H); 2.20 (s) and 2.10 (s) (alltogether 3H).

#### Example 14

(2R,3R,4R)-1-Allyl-3,4-dibenzyloxy-2-benzyloxymethyl-pyrrolidine (Compound 14)

(2R,3R,4R)-3,4-Dibenzyloxy-2-benzyloxymethylpyrrolidine (Compound 1) (1.025 g, 2.5 mmol) was dissolved in methylisobutylketone (15 ml). Triethylamine (0.53 ml, 3.8 mmol) and potassium iodide (0.04 g) were added. The mixture was stirred under a nitrogen atmosphere for 4 hours at 80°C and 24 hours at room temperature and evaporated in vacuo. Water (40 ml) was added and extraction with methylene chloride (3 x 40 ml), drying of the organic phases with magnesium sulphate and evaporation of the solvent in vacuo afforded a yellow oil. Purification of the crude product on a silica gel column (Eluent: Heptane/ethyl acetate (9:1)) gave (2R,3R,4R)-1-allyl-3,4-dibenzyloxy-2-benzyloxymethyl-pyrrolidine (0.91 g, yield: 81%) as an oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) in ppm: δ 7.28 (m, 15H); 6.02-5.82 (m, 1H); 5.25-5.05 (m, 2H); 4.50 (m, 4H); 4.45 (s) and 4.43 (s) (alltogether 2H); 3.89 (m, 2H); 3.67-3.48 (m, 3H); 3.20 (s) and 3.13 (s) (alltogether 1H); 3.02 (dd, 1H); 2.78 (dd, 1H); 2.60 (dd, 1H).

#### Example 15

(2R,3R,4R)-3,4-Dihydroxy-2-hydroxymethyl-1-propylpyrrolidine (Compound 15)

The title compound was synthesized as described for compound 9 using (2R,3R,4R)-1-allyl-3,4-dibenzyloxy-2-benzyloxymethylpyrrolidine (compound 14) (0.910 g, 2.1 mmol), ethanol (100 ml), 10% Pd/C (0.2 g) and excess of 1 M hydrochloric acid to convert the amine to the hydrochloride salt. After evaporation of the solvent in vacuo the compound was purified on silica gel (Eluent: 2-propanol/25% ammonium hydroxide (4:1)) and (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethyl-1-propylpyrrolidine was obtained as a yellow crystals (0.279 g, yield: 78%). Melting point: 79-80°C.

<sup>1</sup>H-NMR (CD<sub>3</sub>OD) in ppm: δ 3.92 (m, 2H); 3.67 (m, 2H); 3.03 (s) and 2.98 (s) (altogether 1H); 2.87-2.59 (m, 2H); 2.46-2.20 (m, 2H); 1.50 (m, 2H); 0.90 (t, 3H).

#### Example 16

15 (2R,3R,4R)-1-Benzyl-3,4-dihydroxy-2-hydroxymethylpyrrolidine (Compound 16)

(2R,3R,4R)-2-Hydroxy-3,4-dihydroxymethylpyrrolidine hydrochloride (compound 2) (0.265 g, 1.6 mmol) was dissolved in dry methanol (25 ml), and benzaldehyde (0.159 ml, 1.6 mmol) and sodium cyanoborohydride (0.098 g, 1.6 mmol) was added. A solution of anhydrous hydrogen chloride in diethylether (2M) was added dropwise until pH 6. The resulting mixture was stirred for 24 hours at room temperature under a nitrogen atmosphere and evaporated in vacuo. Purification of the product on silica gel (Eluent: 2-propanol/methanol (4:1)) afforded (2R,3R,4R)-1-benzyl-3,4-dihydroxy-2-hydroxymethylpyrrolidine (0.304 g, yield: 87%) as an oil.

<sup>1</sup>H-NMR (CD<sub>3</sub>OD) in ppm: δ 7.40-7.20 (m, 5H); 4.10 (d, J = 14Hz, 1H); 3.92 (m, 2H); 3.70 (m, 2H); 3.50 (d, J = 14Hz, 1H); 2.90-2.60 (m, 3H).

Example 17

(2R,3R,4R)-3,4-Dibenzyloxy-2-benzyloxymethyl-1-(2,3-dihydroxyprop-1-yl)pyrrolidine (Compound 17)

The title compound was synthesized as described for compound 5 10 using (2R,3R,4R)-3,4-dibenzyloxy-2-benzyloxymethylpyrrolidine (Compound 1) (0.5 g, 1.2 mmol), methanol (30 ml), glyceraldehyde (0.134 g, 1.5 mmol) and sodium cyanoborohydride (0.094 g, 1.5 mmol). Purification of the crude product on silica gel (Eluent: Ethyl acetate) afforded 10 (2R,3R,4R)-3,4-dibenzyloxy-2-benzyloxymethyl-1-(2,3-dihydroxyprop-1-yl)pyrrolidine (0.424 g, yield: 72%) as an oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) in ppm: δ 7.28 (m, 15H); 4.48 (s, 4H); 4.43 (m, 2H); 3.95 (m, 1H); 3.84 (m, 1H); 3.78-3.25 (m, 8H); 15 3.23 (s) and 3.18 (s) (altogether 1H); 3.02-2.39 (m, 4H).

Example 18

(2R,3R,4R)-3,4-Dihydroxy-2-hydroxymethyl-1-(2,3-dihydroxyprop-1-yl)pyrrolidine, hydrochloride (Compound 18)

The title compound was synthesized as described for compound 20 9 using (2R,3R,4R)-3,4-dibenzyloxy-2-benzyloxymethyl-1-(2,3-dihydroxyprop-1-yl)pyrrolidine (Compound 17) (0.424 g, 0.89 mmol), ethanol (80 ml), 10% Pd/C (0.1 g), and excess of 4 M hydrochloric acid to convert the amine to the hydrochloride salt. (2R,3R,4R)-3,4-Dihydroxy-2-hydroxymethyl-1-(2,3- 25 dihydroxyprop-1-yl)pyrrolidine hydrochloride was obtained as white crystals (0.216 g, yield: 100%) with melting point above 230°C (decomposition).

<sup>1</sup>H-NMR (CD<sub>3</sub>OD) in ppm: δ 4.22 (broad s, 1H); 4.0 (m, 4H); 3.8-3.2 (m, 7H).

Example 19

(2R,3R,4R)-3,4-Dibenzyloxy-2-benzyloxymethyl-1-(2-phthalimidoethyl)pyrrolidine (Compound 19)

- (2R,3R,4R)-3,4-Dibenzyloxy-2-benzyloxymethylpyrrolidine  
5 (Compound 1) (0.73 g, 1.8 mmol), N-(2-bromoethyl)phthalimide (0.686 g, 2.7 mmol), triethylamine (0.5 ml, 3.6 mmol) and a catalytic amount of potassium iodide was dissolved in dry dimethylformamide (30 ml). The mixture was stirred for 24h at 70°C, cooled to room temperature and evaporated in vacuo.  
10 Water (60 ml) was added and extraction with methylene chloride (3 x 60 ml), drying of the organic phases with magnesium sulphate and evaporation of the solvent in vacuo afforded an oil. Purification twice on silica gel (Eluent 1: Heptane/ethyl acetate (1:1) and eluent 2: Petroleum  
15 ether/diethylether (2:1)) gave (2R,3R,4R)-3,4-dibenzyloxy-2-benzyloxymethyl-1-(2-phthalimidoethyl)pyrrolidine (0.64 g, yield: 61%) as an oil.

- <sup>1</sup>H-NMR (CDCl<sub>3</sub>) in ppm: δ 7.72 (m, 2H); 7.60 (m, 2H); 7.24 (m, 15H); 4.50 (m, 4H); 4.40 (m, 2H); 4.00-3.64 (m,  
20 4H); 3.53-3.23 (m, 4H); 2.79 (dd, 1H); 2.28 (dd, 1H); 2.7-2.5 (m, 1H).

Example 20

(2R,3R,4R)-1-(2-Aminoethyl)-3,4-dibenzyloxy-2-benzyloxymethylpyrrolidine (Compound 20)

- 25 (2R,3R,4R)-3,4-Dibenzyloxy-2-benzyloxymethyl-1-(2-phthalimidoethyl)pyrrolidine (Compound 19) (0.64 g, 1.1 mmol) was dissolved in ethanol (20 ml) and hydrazin, hydrate (0.215 ml, 4.4 mmol) was added. The clear solution was stirred for 4 hours at 40°C and for 18 hours at room temperature. The  
30 white precipitate was filtered off and the filtrate



evaporated in vacuo. The residue was partitioned between aqueous hydrochloric acid and methylene chloride. The water phase adjusted to pH 11 with 2N sodium hydroxide and extracted with methylene chloride (2 x 100 ml) and with  
5 diethylether (100 ml). Drying of the combined organic phases with magnesium sulphate and evaporation of the solvent in vacuo afforded the crude product as an oil. Purification on silica gel (Eluent: Ethyl acetate) gave (2R,3R,4R)-1-(2-aminoethyl)-3,4-dibenzyloxy-2-benzyloxymethylpyrrolidine  
10 (0.015 g) as an oil.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) in ppm: δ 7.22 (m, 15H); 4.50 (m, 4H); 4.40 (m, 2H); 3.95 (m, 1H); 3.83 (m, 1H); 3.65-3.30 (m, 4H); 3.29 (s) and 3.24 (s) (altogether 1H); 3.13-2.98 (m, 1H); 2.82 (dd, 1H); 2.67 (dd, 1H); 2.6 (m, 1H).

15

#### Example 21

(2R,3R,4R)-1-(2-Aminoethyl)-3,4-dihydroxy-2-hydroxymethylpyrrolidine (Compound 21)

The title compound can be synthesized as described for compound 9 using (2R,3R,4R)-1-(2-aminoethyl)-3,4-dibenzyloxy-2-benzyloxymethylpyrrolidine (Compound 20) as  
20 starting material.

#### Example 22

(2R,3R,4R)-3,4-Dibenzyloxy-2-benzyloxymethyl-1-(2-hydroxyethyl)pyrrolidine (Compound 22)

25 The title compound was prepared as described for compound 8 using (2R,3R,4R)-3,4-dibenzyloxy-2-benzyloxymethylpyrrolidine (Compound 1) (0.51 g, 1.27 mmol) and 2-chloroethanol (0.1 ml, 1.49 mmol) as starting material. (2R,3R,4R)-3,4-

Dibenzyloxy-2-benzyloxymethyl-1-(2-hydroxyethyl)pyrrolidine was obtained as a golden oil (0.48 g, yield: 85 %).

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) in ppm: δ 7.3 (m, 15H); 4.5 (m, 6H); 4.0 (broad d, 1H); 3.9 (broad d, 1H); 3.6 (m, 4H); 3.25 (d, 1H); 3.05 (m, 1H); 2.9 (m, 1H); 2.68 (dd, 1H); 2.6 (dt, 1H).

#### Example 23

(2R,3R,4R)-3,4-Dihydroxy-1-(2-hydroxyethyl)-2-hydroxymethylpyrrolidine, hydrochloride (Compound 23)

The title compound was synthesized as described for compound 9 using (2R,3R,4R)-3,4-dibenzyloxy-2-benzyloxymethyl-1-(2-hydroxyethyl)pyrrolidine (Compound 22) as starting material. (2R,3R,4R)-3,4-Dihydroxy-1-(2-hydroxyethyl)-2-hydroxymethylpyrrolidine, hydrochloride was obtained as an golden oil (0.23 g, yield 100%).

<sup>1</sup>H-NMR (CD<sub>3</sub>OD) in ppm: δ 4.2 (broad s, 1H), 3.85-4.05 (m, 5H); 3.5-3.8 (m, 4H); 3.25-3.4 (m, 1H)

#### Example 24

#### Experimental protocol and results

For in vivo studies, female ob/OB mice (20 g) fasted for 3 hours were used. Test compounds or NaCl (0.9%; controls) were administered intravenously (hereinafter designated i.v.). Glucagon were administered subcutaneously (hereinafter designated s.c.) in order to increase hepatic glucose output derived from glycogen. Blood samples were drawn from the orbital vain and analyzed for glucose using a glucose oxidase method.

Rat hepatocytes were isolated using a standard two step collagenase technique, and cultured onto collagen coated

culture dishes for 72 hours in medium 199 with the addition of dexamethazone (0.1  $\mu$ M); penicillin/Streptomycin ((100 u/100  $\mu$ g)/ml) and insulin (1 nM). During the last 24 hours, the hepatocytes were cultured in the presence of high levels  
5 of insulin (5 nM) and glucose (15 mM), which result in the incorporation of glucose into glycogen. Therefore, at the time of the experiment, the cells mimic livers from fed animals.

Experiments were initiated after 48 hours of culture by  
10 2 times wash of cells and addition of a 20 mM HEPES experimental buffer including balanced salts, but without glucose. The test compound was added simultaneously with the experimental buffer. To some cultures, glucagon (0.5 nM) was added after 10 minutes in order to stimulate glucose produc-  
15 tion from liver cells. The glucose released into the media, reflecting the glucose production of the liver cells, was measured 70 minutes after the start of the experiment and standardized to cellular DNA content.

Phosphorylase was either purchased from Sigma or extracted  
20 from rat livers according to Stalmans et. al. (Eur.J.Biochem. 49 (1974), 415). The activity of phosphorylase was determined as described by Bergmeyer (1983; in: Meth. of Enzymatic Analysis, 2, 293-295, Weinheim, (ed.) Verlag Chemie).

25 The activity of the glycogen debranching enzyme,  $\alpha$ -1,6-glucosidase, was determined as described by Brown and Brown (1966; in : Meth. in Enzymology, 8, 515-524, Neufeld and Ginsburg (Eds.) Academic Press).

Table 1 below demonstrate the efficacy of (2R,3R,4R)-3,4-  
30 dihydroxy-2-hydroxymethylpyrrolidine (Compound 2) in lowering the glucagon mediated increase in plasma glucose. The effects are compared to those in control animals and

those in animals treated with 6 fold higher doses of the model  $\alpha$ -1,6-glucosidase inhibitor 1-deoxynojirimycin (hereinafter designated dNOJ).

5 Table 1. Effects of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine and the model $\alpha$ -1,6-glucosidase inhibitor on the glucagon mediated increase in blood glucose in mice. Numbers are averages $\pm$ S.D.. N=5.	
	Delta plasma glucose (mmoles/L)
Control animals	6.3 $\pm$ 1.0
10 Compound 2 (8 mg/kg)	0.5 $\pm$ 0.6
dNOJ (50 mg/kg)	5.7 $\pm$ 1.2

Table 1 demonstrates that (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine (Compound 2) represents a potent  
15 principle for reducing blood glucose. In contrast, the  $\alpha$ -1,6-glucosidase inhibitor, dNOJ, was unable to reduce blood glucose.

Table 2 below shows the results obtained with (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine (Compound 2) on  
20 basal and glucagon stimulated glycogenolysis. The effects are compared to those exerted by the  $\alpha$ -1,6-glucosidase inhibitor: dNOJ.

5 Table 2. Effects of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine (Compound 2) on baseline and glucagon stimulated glucose production from cultured liver cells. Values are expressed relative to the basal glucose production. Results obtained with the model  $\alpha$ -1,6 glucosidase inhibitor, 1-deoxynojirimycin, are shown for comparison.

	<u>Glucose production</u>	
	Without glucagon	With glucagon (0.5nM)
No addition:	100 %	233%
Compound 2 (1 $\mu$ M):	19 %	41%
10 dNOJ (50 $\mu$ M):	92 %	195%

The results clearly demonstrate the ability of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine (Compound 2) to inhibit basal and glucagon stimulated hepatocyte glucose production, while inhibition of  $\alpha$ -1,6-glucosidase (dNOJ) was 15 insufficient to suppress hepatic glucose production.

Table 3 compares the potency of various 2-methylpyrrolidines with the potency of dNOJ on various cellular and enzymatic activities.

Table 3. Effects of selected pyrrolidines compared to effects of dNOJ on different enzymatic activities. The results are the concentrations of the compounds resulting in half maximal activity (I.C. <sub>50</sub> $\mu$ moles/l).		
Compound	Phospho-rylase	1,6-glucosidase
dNOJ	>200	1.1
2	0.7	0.18 <sup>a</sup>
23	10	n.d.
7	145	n.d.
9	169	n.d.
11	60	n.d.

n.d.: not determined

<sup>a</sup>) From: Fleet et al. (Tetrahedron 20 (1986), 5685)

15 It is apparent from the presented data in table 3 that the 2-methylpyrrolidines of this invention are potent inhibitors of liver cell glucose production. Moreover, it is also demonstrated that phosphorylase is inhibited by these compounds in similar low concentrations.

20 Table 3 also demonstrates that the potent model inhibitor of liver  $\alpha$ -1,6-glucosidase was unable to inhibit either liver cell glucose production or phosphorylase.

While  $\alpha$ -1,6-glucosidase inhibition is recognized as a principle of reducing blood glucose in association with a carbohydrate rich meal, the finding that compounds of this invention are able to reduce blood glucose arising from hepatic glucose production, i.e. blood glucose in the

fasting state, is new and surprising. The surprising aspect is substantiated by the presented negative results with the model  $\alpha$ -1,6-glucosidase inhibitor: dNOJ. These results are in agreement with the results presented by Bollen and Stalmans (Eur.J.Biochem. 181 (1980), 775), who also concluded that  $\alpha$ -1,6-glucosidase inhibition is an insufficient principle for inhibition of liver cell glucose production. Furthermore, it was clearly demonstrated by Sels et al. (Netherland J.Med. 44 (1994), 198) that fasting plasma glucose of type 2 diabetic patients was not reduced after treatment with the  $\alpha$ -1,6-glucosidase inhibitor, miglitol.

In conclusion, the data demonstrates that the compounds of this invention are able to reduce blood glucose and inhibits glucose production from liver cells. It is also demonstrated that the reduction in blood glucose and liver cell glucose production by the compounds of formula I according to this invention is mediated by inhibition of phosphorylase. Consequently, the compounds of formula I can be used to inhibit both the baseline and glucagon stimulated glucose production from liver cells. Therefore, compounds of formula I will be usefull in the treatment of diabetes.

Example 25**Tablets**

Tablets which are suitable for oral administration and which contain the below-mentioned components are produced in a manner known per se granulating the active and the auxiliary substances and making them into tablets.

A typical tablet contains 50 mg of the compound of formula I, 100 mg of lactose, 30 mg of corn starch, 3 mg of talc powder, 3 mg of colloidal silicon dioxide and 2 mg of magnesium stearate.

Example 26**Capsules**

Capsules which are suitable for oral administration contain the below-mentioned components are produced in a manner known per se mixing the active substances with the auxiliary substances and putting them into gelatine capsules.


A typical capsule contains 50 mg of the compound of formula I, 100 mg of lactose, 30 mg of corn starch, 3 mg of talc



powder, 3 mg of colloidal silicon dioxide and 2 mg of magnesium stearate.

CLAIMS

1. The use of compounds of the general formula I



(I)

wherein R<sup>1</sup> is hydrogen, acyl, alkene, cycloalkyl or alkyl  
5 which optionally is substituted with one or more of the  
following groups: hydroxy, alkoxy, amino, N-alkylamino, N,N-  
dialkylamino, halogen, cycloalkyl, optionally substituted  
phenyl or alkoxycarbonyl, R<sup>2</sup> is hydrogen or alkyl, R<sup>3</sup> and  
R<sup>4</sup>, which are the same or different, independent of each  
10 other, is hydrogen, halogen, hydroxy, mercapto or amino  
which is optionally substituted with alkyl or aralkyl, and  
R<sup>5</sup> is alkyl substituted with hydroxy, halogen, amino, N-  
alkylamino, N,N-dialkylamino or mercapto, or salts or  
hydrates thereof as a liver glycogen phosphorylase  
15 inhibitory agent.

2. The use, according to claim 1, wherein the compound of formula I contains at least 2 hydroxy groups.
3. The use, according to anyone of the previous claims, wherein the compound of formula I contains at least 3  
5 hydroxy groups.
4. The use, according to anyone of the previous claims, wherein in the compound of formula I the two substituents designated by the symbols  $R^3$  and  $R^5$  are situated at the same side of the plane formed by the 5 membered nitrogen  
10 containing ring, and  $R^4$  is situated at the opposite side of the plane formed by the 5 membered nitrogen containing ring.
5. The use, according to anyone of the previous claims, wherein in the compound of formula I  $R^1$  represents hydrogen, acyl or alkyl which is optionally substituted with one or  
15 more of the following groups: hydroxy, alkoxy, amino, N-alkylamino, N,N-dialkylamino, phenyl or alkoxycarbonyl.
6. The use, according to the previous claim, wherein in the compound of formula I  $R^1$  is hydrogen or alkyl, preferably methyl.
- 20 7. The use, according to the previous claim, wherein in the compound of formula I  $R^1$  is hydrogen.

8. The use, according to anyone of the previous claims,  
wherein in the compound of formula I the optionally  
substituted phenyl group is phenyl substituted with one or  
more of the following groups: halogen, hydroxy, alkoxy,  
5 trifluoroalkyl or cyano.
9. The use, according to anyone of the previous claims,  
wherein in the compound of formula I  $R^2$  is hydrogen or  
alkyl, preferably methyl.
10. The use, according to anyone of the previous claims,  
10 wherein in the compound of formula I  $R^2$  is hydrogen.
11. The use, according to anyone of the previous claims,  
wherein in the compound of formula I  $R^3$  is hydrogen,  
hydroxy, halogen or amino.
12. The use, according to anyone of the previous claim,  
15 wherein in the compound of formula I  $R^3$  is hydroxy, halogen  
or amino.
13. Compounds, according to the previous claim, wherein  $R^3$   
is hydroxy or halogen, preferably fluoro.
14. The use, according to the previous claim, wherein  $R^3$  is  
20 hydroxy.

15. The use, according to anyone of the previous claims, wherein in the compound of formula I  $R^4$  is hydrogen, hydroxy, halogen or amino.

16. The use, according to anyone of the previous claims, wherein in the compound of formula I  $R^4$  is hydroxy, halogen or amino.

17. The use, according to anyone of the previous claims, wherein in the compound of formula I  $R^4$  is hydrogen or halogen, preferably fluoro.

18. The use, according to anyone of the previous claims, wherein in the compound of formula I  $R^4$  is hydroxy or halogen, preferably fluoro.

19. The use, according to the previous claim, wherein  $R^4$  is hydroxy.

20. The use, according to anyone of the previous claims, wherein in the compound of formula I  $R^5$  is hydroxyalkyl.

21. The use, according to anyone of the previous claims, wherein in the compound of formula I  $R^5$  is hydroxymethyl, hydroxyethyl or hydroxypropyl, preferably hydroxymethyl.

22. The use, according to anyone of the previous claims, wherein in the compound of formula I  $R^5$  is hydroxymethyl.
23. The use, according to anyone of the previous claims, wherein in the compound of formula I  $R^5$  is hydroxymethyl or  
5 benzyloxymethyl, preferably hydroxymethyl.
24. The use of a compound of formula I defined in anyone of the preceding claims for the manufacture of a pharmaceutical composition for the treatment of diabetes.
25. The use of a compound of formula I defined in anyone of  
10 the preceding claims for the manufacture of a pharmaceutical composition inhibiting the glucose production from the liver.
26. A pharmaceutical composition containing a compound of formula I defined in anyone of the preceding claims in  
15 connection with a pharmaceutically acceptable carrier.
27. A method of treating diabetes which method comprises administering an effective amount of a compound of formula I defined in anyone of the preceding claims to a patient in need of such a treatment.

28. A method of inhibiting the liver glucose production from the liver which method comprises administering an effective amount of a compound of formula I defined in anyone of the preceding claims to a patient in need of such  
5 a treatment.

29. The use of a compound, according to anyone of the previous use, composition or method claims, which is 3,4-dihydroxy-2-hydroxymethylpyrrolidine, 3,4-dihydroxy-2-hydroxymethyl-1-methylpyrrolidine, 1-cyclopropylmethyl-3,4-  
10 dihydroxy-2-hydroxymethylpyrrolidine, 3,4-dihydroxy-2-hydroxymethyl-1-propylpyrrolidine, 1-butyl-3,4-dihydroxy-2-hydroxymethylpyrrolidine, 3,4-dihydroxy-2-hydroxymethyl-1-(2,2,2-trifluoroethyl)pyrrolidine, 1-benzyl-3,4-dihydroxy-2-hydroxymethylpyrrolidine, 3,4-dihydroxy-2-hydroxymethyl-1-  
15 (2-hydroxyethyl)pyrrolidine, 3,4-dihydroxy-2-hydroxymethyl-1-(1,3-dihydroxyprop-2-yl)pyrrolidine, 3,4-dihydroxy-2-hydroxymethyl-1-(2,3-dihydroxyprop-1-yl)pyrrolidine, 1-(2-aminoethyl)-3,4-dihydroxy-2-hydroxymethylpyrrolidine, preferably 3,4-dihydroxy-2-hydroxymethylpyrrolidine and any  
20 of the optical isomers thereof.

30. The use of a compound, according to the previous claim, which is (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine, (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethyl-1-methylpyrrolidine, (2R,3R,4R)-1-cyclopropylmethyl-3,4-di-

hydroxy-2-hydroxymethylpyrrolidine, (2R,3R,4R)-3,4-di-  
hydroxy-2-hydroxymethyl-1-propylpyrrolidine, (2R,3R,4R)-1-  
butyl-3,4-dihydroxy-2-hydroxymethylpyrrolidine, (2R,3R,4R)-  
3,4-dihydroxy-2-hydroxymethyl-1-(2,2,2-trifluoroethyl)-  
5 pyrrolidine, (2R,3R,4R)-1-benzyl-3,4-dihydroxy-2-hydroxy-  
methylpyrrolidine, (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethyl-  
1-(2-hydroxyethyl)pyrrolidine, (2R,3R,4R)-3,4-dihydroxy-2-  
hydroxymethyl-1-(2,3-dihydroxyprop-1-yl)pyrrolidine,  
(2R,3R,4R)-3,4-dihydroxy-2-hydroxymethyl-1-(1,3-dihydroxy-  
10 prop-2-yl)pyrrolidine, (2R,3R,4R)-1-(2-aminoethyl)-3,4-di-  
hydroxy-2-hydroxymethylpyrrolidine, (2S,3S,4S)-3,4-di-  
hydroxy-2-hydroxymethylpyrrolidine, (2S,3S,4S)-3,4-di-  
hydroxy-2-hydroxymethyl-1-methylpyrrolidine, (2S,3S,4S)-1-  
cyclopropylmethyl-3,4-dihydroxy-2-hydroxymethylpyrrolidine,  
15 (2S,3S,4S)-3,4-dihydroxy-2-hydroxymethyl-1-propyl-  
pyrrolidine, (2S,3S,4S)-1-butyl-3,4-dihydroxy-2-hydroxy-  
methylpyrrolidine, (2S,3S,4S)-3,4-dihydroxy-2-hydroxymethyl-  
1-(2,2,2-trifluoroethyl)pyrrolidine, (2S,3S,4S)-1-benzyl-  
3,4-dihydroxy-2-hydroxymethylpyrrolidine, (2S,3S,4S)-3,4-di-  
20 hydroxy-2-hydroxymethyl-1-(2-hydroxyethyl)pyrrolidine,  
(2S,3S,4S)-3,4-dihydroxy-2-hydroxymethyl-1-(2,3-dihydroxy-  
prop-1-yl)pyrrolidine, (2S,3S,4S)-3,4-dihydroxy-2-hydroxy-  
methyl-1-(1,3-dihydroxyprop-2-yl)pyrrolidine, (2S,3S,4S)-1-  
(2-aminoethyl)-3,4-dihydroxy-2-hydroxymethylpyrrolidine,  
25 preferably (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethyl-  
pyrrolidine.



31. Any novel feature or combination of features described herein.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 96/00373

## A. CLASSIFICATION OF SUBJECT MATTER

IPC6: A61K 31/40, C07D 207/12

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS-ONLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0389723 A1 (MERRELL DOW PHARMACEUTICALS INC.), 3 October 1990 (03.10.90) --	24,25
A	EP 0422307 A1 (MERRELL DOW PHARMACEUTICALS INC.), 17 April 1991 (17.04.91) --	24,25
X	EP 0367747 A2 (G.D.SEARLE & COMPANY), 9 May 1990 (09.05.90)	13,26
A	--	24,25

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

- \* Special categories of cited documents
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

25 November 1996

Date of mailing of the international search report

06.12.96

Name and mailing address of the ISA/  
Swedish Patent Office  
Box 5055, S-102 42 STOCKHOLM  
Facsimile No. +46 8 666 02 86

Authorized officer

Göran Karlsson

Telephone No. +46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 96/00373

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0322395 A1 (MONSANTO COMPANY), 28 June 1989 (28.06.89)	13,26
A	--	24,25
X	US 4973602 A (FRANCIS J. KOSZYK ET AL), 27 November 1990 (27.11.90)	13,26
A	-- -----	24,25

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 96/00373

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-12, 15-23, 27-30  
because they relate to subject matter not required to be searched by this Authority, namely:  
A method for treatment of the human or animal body by therapy,  
see rule 39.1.
2. ☒ Claims Nos.: 14 and 31  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
Claims 14 and 31 are obscure and do not define the matter for which protection is sought. A meaningful search of these claims has therefore not been performed, see Article 6.
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT  
Information on patent family members

28/10/96

International application No.  
PCT/DK 96/00373

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A1- 0389723	03/10/90	AU-A- 5217990	04/10/90
		CA-A- 2013382	29/09/90
		CN-A- 1045975	10/10/90
		EP-A- 0390674	03/10/90
		JP-A- 2268154	01/11/90
EP-A1- 0422307	17/04/91	AT-T- 109153	15/08/94
		AU-B- 632855	14/01/93
		AU-A- 6375690	18/04/91
		CA-A- 2027276	11/04/91
		CN-B- 1029974	11/10/95
		CN-A- 1050879	24/04/91
		DE-D, T- 69011033	17/11/94
		EP-A, B- 0422975	17/04/91
		SE-T3- 0422975	
		ES-T- 2060980	01/12/94
		HU-B- 209724	28/10/94
		IE-B- 64079	12/07/95
		IL-A- 95928	26/08/94
		JP-A- 3127797	30/05/91
		NO-B, C- 174203	20/12/93
		US-A- 5097023	17/03/92
EP-A2- 0367747	09/05/90	SE-T3- 0367747	
		AT-T- 135346	15/03/96
		CA-A- 2002105	03/05/90
		DE-D, T- 68925940	24/10/96
		ES-T- 2086323	01/07/96
		JP-A- 2172972	04/07/90
		US-A- 4876268	24/10/89
		US-A- 4937357	26/06/90
EP-A1- 0322395	28/06/89	US-A- 4973602	27/11/90
		SE-T3- 0322395	
		AU-A- 2706888	22/06/89
		CA-A- 1316929	27/04/93
		DE-A, T- 3879653	29/04/93
		FI-B, C- 93210	30/11/94
		IE-B- 63095	22/03/95
		JP-A- 1230517	14/09/89
		OA-A- 8937	31/10/89
		PT-B- 89267	31/12/93
		US-A- 4999360	12/03/91
		US-A- 5089520	18/02/92
		US-A- 5043416	27/08/91

# INTERNATIONAL SEARCH REPORT

28/10/96

International application No.

PCT/DK 96/00373

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US-A- 4973602	27/11/90	AT-T- 135346	15/03/96	
		CA-A- 2002105	03/05/90	
		DE-D, T- 68925940	24/10/96	
		EP-A, B- 0367747	09/05/90	
		SE-T3- 0367747		
		ES-T- 2086323	01/07/96	
		JP-A- 2172972	04/07/90	
		US-A- 4876268	24/10/89	
		US-A- 4937357	26/06/90	
<hr/>				

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**